The National Institute for Health and Care Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on percutaneous coblation of the intervertebral disc for low back pain and sciatica in January 2016.
V60.- Primary percutaneous decompression using coblation to intervertebral disc
V55.- Levels of spine
V61.- Revisional percutaneous decompression using coblation to intervertebral disc
V55.- Levels of spine
Note: Codes within categories V60 and V61 specify the area of the spine where the operation takes place. If the area of spine is not specified, the code V60.9 Unspecified primary percutaneous decompression using coblation to intervertebral disc or V61.9 Unspecified revisional percutaneous decompression using coblation to intervertebral disc is used.
Note: Codes within category V55.- are assigned in second place each time a spinal operation is coded. If the levels of spine are not specified, the code V55.9 Unspecified levels of spine is used.
IIn addition the ICD-10 code M54.5 Low back pain or M54.3 Sciatica would be recorded.
This interventional procedure guidance replaces previous guidance on percutaneous disc decompression using coblation for lower back pain (NICE interventional procedure guidance 173).
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.